Table 2.
Clinical profile of COVID-19 infection and convalescent plasma therapy.
| Characteristics | N = 33 |
|---|---|
| Fever | 33 (100%) |
| Cough | 20 (60.6%) |
| Breathlessness | 22 (66.7%) |
| Severe Covid-19 infection | 33 (100%) |
| Median duration of hospital stay (range) | 14 days (2–39) |
| Need for ICU stay | 23 (69.7%) |
| Oxygen support | |
| Oxygen by mask | 27 (81.8%) |
| Non-invasive ventilation | 16 (48.5%) |
| Invasive ventilation | 14 (42.4%) |
| Need for vasopressor support | 15 (45.5%) |
| Single inotrope support | 10 (30.3%) |
| Double inotrope support | 5 (15.2%) |
| Median day of plasma infusion from date of diagnosis (range) | 4 (1 to 25) |
| Plasma infusion < 7 days | 25 (75.8%) |
| Plasma infusion ≥ 7 days | 8 (24.2%) |
| Plasma infusion ≤ 3 days | 16 (48.5%) |
| Plasma infusion > 3 days | 17 (51.5%) |
| Median number of times plasma was infused (range) | 1 (1 to 2) |
| 1 plasma infusion | 18 (54.5%) |
| 2 plasma infusion | 15 (45.5%) |
| Mortality | |
| 14-day mortality | 8 (24.2%) |
| 28-day mortality | 11 (33.3%) |
| 42- day mortality (overall mortality) | 15 (45.5%) |